Status:
TERMINATED
A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate t...
Eligibility Criteria
Inclusion
- Is a healthy adult 18 to 75 years of age, inclusive, in general good health and with diagnosis of knee OA, as determined by the American College of Rheumatology (ACR) clinical/radiographic classification criteria for OA of the knee.
- Women must be of non childbearing potential (amenorrhea for at least 1 year PLUS have a serum follicle stimulating hormone (FSH) level \>30 IU/L, bilateral oophorectomy or hysterectomy), and have a confirmed negative serum pregnancy test at the screening visit prior to randomization.
Exclusion
- History of other diseases that may involve the study joint, including inflammatory joint diseases, crystalline disease, endocrinopathies, metabolic diseases, infections, neuropathic disorders, avascular necrosis, Paget's disease, or tumors.
- Women of childbearing potential, or who are pregnant or lactating.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT00418782
Start Date
January 1 2007
End Date
August 1 2007
Last Update
December 5 2018
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anniston, Alabama, United States, 36207
2
Pfizer Investigational Site
Bayou La Batre, Alabama, United States, 36509
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
4
Pfizer Investigational Site
Birmingham, Alabama, United States, 35216